Since all patients of our cohort were KRAS mutated in cfDNA by BEAMing, we evaluated the specificity of TST170 based on the status of NRAS, another relevant gene for CRC that was WT in cfDNA by BEAMing analysis for most of the patients of our cohort (Table 1). This evidence concerns the gene KRAS and colorectal carcinoma.